Center-Authored Papers

Filters: Author is Bensinger, William I  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DEH, Singhal AK.  2011.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.. Blood. 120(3):552-559. Abstract
Zaucha R, Gooley TA, Holmberg L, Gopal AK, Press OW, Maloney DG, Bensinger WI.  2008.  High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.. Leukemia & lymphoma. 49(10):1899-906. Abstract
Y
Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN et al..  2016.  Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.. The Lancet. Oncology. 17(11):1569-1578. Abstract
W
Wang M, Martin T, Bensinger WI, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R.  2013.  Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma.. Blood. 122(18):3122-8. Abstract
T
Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger WI, Press OW.  2008.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.. Leukemia & lymphoma. 49(6):1062-73. Abstract
S
Stiff PJ, Bensinger WI, Abidi MH, Gingrich R, Artz AS, Nademanee A, Hansen KS, Sobczak C, Cutler C, Bolwell B et al..  2009.  Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(7):827-34. Abstract
Stewart KA, Rajkumar VS, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG et al..  2015.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.. The New England journal of medicine. 372(2):142-52. Abstract
Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS et al..  2017.  A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.. Cancer. Abstract
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL et al..  2015.  Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma.. Blood. Abstract
R
Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P et al..  2009.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.. Blood. 113(14):3383-91. Abstract
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger WI, Badros AZ, Vescio R et al..  2009.  Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.. Blood. 114(4):772-8. Abstract
P
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI et al..  2015.  Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6. Abstract
N
Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M.  2013.  Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(8):2248-56. Abstract
M
Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, Inamoto Y, Chauncey TR, Storb R, Appelbaum FR et al..  2012.  Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.. Blood. 119(11):2675-2678. Abstract
K
Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J et al..  2014.  Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: results from a phase 1 study.. Blood. Abstract
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R et al..  2009.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.. Blood. 114(9):1729-35. Abstract
Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger WI, Djulbegovic B, Kumar A.  2013.  Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.. Journal of hematology & oncology. 6:2. Abstract
Keeney GE, Gooley TA, Pham RN, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Bensinger WI, Holmberg L, Gopal AK.  2007.  The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation.. Leukemia & lymphoma. 48(10):1961-7. Abstract
J
Jakubowiak AJ, Benson DM, Bensinger WI, Siegel DSD, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DEH, Singhal AK, Anderson KC.  2012.  Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(16):1965. Abstract
H
Holmberg LA, Becker PS, Bensinger WI.  2017.  Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.. Acta haematologica. 137(3):123-131. Abstract
Hammond SP, Swaminathan S, Bensinger WI, Baden LR.  2014.  Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(12):1655-7.
G
Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer BE, Zaia JA, Forman S, Negrin RS, Chauncey TR, Bensinger WI et al..  2012.  Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1):66-75. Abstract
Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL et al..  2014.  A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.. Cancer research. 74(4):1179-89. Abstract
Green DJ, Bensinger WI.  2017.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? Current hematologic malignancy reports. Abstract
Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW et al..  2016.  Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(9):1582-1587. Abstract